Country: South Africa
Language: English
Source: South African Health Products Regulatory Authority (SAHPRA)
Aspen-p
MESASAL TABLETS 250 mg MESASAL TABLETS 500 mg (DISCONTINUED)* SCHEDULING STATUS: S3 PROPRIETARY NAME (and dosage form): MESASAL TABLETS 250 mg MESASAL TABLETS 500 mg (DISCONTINUED)* COMPOSITION: Mesasaltablets are controlled release, enteric coated tablets containing either 250 mg or 500 mg of mesalazine (5-amino- salicylic acid) (5-ASA). PHARMACOLOGICAL CLASSIFICATION: A.11.9.2 Antidiarrhoeals (other) PHARMACOLOGICAL ACTION: Pharmacodynamics properties: The mode of the anti-inflammatory action of 5- ASA is unknown although there are several possibilities: • Inhibition of prostaglandin synthesis (via inhibition of cyclo-oxygenase) thereby down-regulating the production of inflammatory prostaglandins. • Inhibition of the chemotactic leukotriene synthesis (via inhibition of lipoxygenase) thereby reducing inflammation. • Inhibition of the macrophage and neutrophil chemotaxis in inflamed tissue • The scavenging of oxygen free radicals Pharmacokinetics properties Oral Administration In patients with Crohn’s disease or ulcerative colitis: • Oral doses of 500 mg mesalazine t.i.d. steady-state plasma concentration of 5-ASA and Ac-5-ASA (its major metabolite) averaged 0.7 and 1.2 mcg/mL, respectively • Oral doses of 250 mg mesalazine t.i.d. steady-state concentration of 5-ASA and Ac-5- ASA averaged 0.4 and 1.0 mcg/mL, respectively Peak drug and metabolism levels with delayed release preparations generally occur about 5 hours after drug administration. Urinary (44%) and faecal (35%) recovery (at the higher dose) indicate that 5-ASA is available both for local and systemic action. Fasted, healthy subjects: Time to peak plasma concentrations of 1.3 mcg/mL and 2.3 mcg/mL of 5- ASA and Ac-5-ASA respectively were obtained after 6 hours INDICATIONS: Mesasalis indicated in: 1. The treatment of acute ul Read the complete document